Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
central nervous system
Biotech
BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug
After axing its lead obesity asset, BioAge has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses
Will Maddox
May 14, 2026 11:00am
Exxel plans $13M IPO to score where other FAAH inhibitors failed
Feb 3, 2026 11:33am
Rethinking heart attacks as the nervous system gone haywire
Jan 27, 2026 11:00am
MapLight brightens SandboxAQ with CNS deal
Dec 16, 2025 7:30am
Lilly pulls out of CNS portion of $960M collab with Rigel
Nov 5, 2025 7:00am
MapLight goes public via $250M IPO to fund Cobenfy competitor
Oct 27, 2025 6:45am
